CLINICAL STUDY
A randomized, placebo-controlled trial of enoxaparin after high-risk coronary stenting: the ATLAST trial
Wayne B. Batchelor, MD, MHS*,
Kenneth W. Mahaffey, MD, FACC*,
Peter B. Berger, MD, FACC ,
Ezra Deutsch, MD ,
Susan Meier, BS ,
Vic Hasselblad, PhD*,
Edward T. Fry, MD||,
Paul S. Teirstein, MD, FACC¶,
Allan M. Ross, MD, FACC#,
Cynthia A. Binanay, RN*,
James P. Zidar, MD, FACC*,* the ATLAST Trial Investigators
* the Duke Clinical Research Institute, Durham, North Carolina, USA
Mayo Clinic, Rochester, Minnesota, USA
New York Presbyterian Hospital, New York, New York, USA
Aventis Pharma, Bridgewater, New Jersey, USA
|| St. Vincents Hospital, Indianapolis, Indiana, USA
¶ Scripps Clinic, La Jolla, California, USA
# George Washington University, Washington, D.C., USA
Manuscript received February 28, 2001;
revised manuscript received July 10, 2001,
accepted August 8, 2001.
* Reprint requests and correspondence: Dr. James P. Zidar, Duke University Medical Center, 7405 Hospital North, Box 3290, Erwin Road, Durham, North Carolina 27710 USA zidar001{at}mc.duke.edu
OBJECTIVES
We performed a multicenter, double-blind placebo-controlled trial to examine the efficacy and safety of enoxaparin in patients at high risk for stent thrombosis (ST).
BACKGROUND
The optimal antithrombotic regimen for such patients is unknown.
METHODS
We randomized 1,102 patients with clinical, angiographic or ultrasonographic features associated with an increased risk of ST to receive either twice-daily injections of weight-adjusted enoxaparin or placebo for 14 days after stenting. All patients received aspirin and ticlopidine. The primary end point was a 30-day composite end point of death, myocardial infarction (MI) or urgent revascularization.
RESULTS
The target enrollment for the study was 2,000 patients. However, the trial was terminated prematurely at 1,102 patients after interim analysis revealed an unexpectedly low event rate. The primary outcome occurred in 1.8% enoxaparin-treated patients versus 2.7% treated with placebo (odds ratio [OR] 0.66; 95% confidence interval [CI] 0.29 to 1.5, p = 0.30); for death or MI the rates were 0.9% vs. 2.2%, respectively (OR 0.41, 95% CI 0.14 to 1.2, p =0.13); and for MI, 0.4% vs. 1.6%, respectively (OR 0.22, 95% CI 0.05 to 0.99, p = 0.04). The groups had comparable rates of major bleeding (3.3% for enoxaparin, 1.6% for placebo, p =0.08), but minor nuisance bleeding was increased with enoxaparin (25% vs. 5.1%, p < 0.001).
CONCLUSIONS
The clinical outcomes of patients at increased risk of ST are more favorable than previously reported, rendering routine oral antiplatelet therapy adequate for most. However, given its relative safety and potential to reduce the risk of subsequent infarction, a 14-day course of enoxaparin may be considered for carefully selected patients.
|
Abbreviations and Acronyms
| | ACS | = acute coronary syndromes | | ATLAST | = Antiplatelet Therapy versus Lovenox plus Antiplatelet Therapy for Patients with an Increased Risk of Stent Thrombosis | | CABG | = coronary artery bypass surgery | | CEC | = Clinical Events Committee | | CK | = creatine kinase | | DSMB | = Data and Safety Monitoring Board | | FDA | = Food and Drug Administration | | LMWH | = low-molecular-weight heparin | | MI | = myocardial infarction | | PCI | = percutaneous coronary intervention | | SC | = Steering Committee | | ST | = stent thrombosis | | TIMI | = Thrombolysis In Myocardial Infarction | | UFH | = unfractionated heparin |
|
This article has been cited by other articles:

|
 |

|
 |
 
K. Makkar, R. L Wilensky, M. B. Julien, H. C Herrmann, and S. A Spinler
Rash with Both Clopidogrel and Ticlopidine in Two Patients Following Percutaneous Coronary Intervention with Drug-Eluting Stents
Ann. Pharmacother.,
June 1, 2006;
40(6):
1204 - 1207.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. N. Levine, G. Raskob, R. J. Beyth, C. Kearon, and S. Schulman
Hemorrhagic Complications of Anticoagulant Treatment: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Chest,
September 1, 2004;
126(3_suppl):
287S - 310S.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Borja, J. Curto, J. Campbell, and M. A. Paz
Enoxaparin after high-risk coronary stenting
J. Am. Coll. Cardiol.,
September 18, 2002;
40(6):
1197 - 1198.
[Full Text]
[PDF]
|
 |
|
|